# EDGAR Filing Document

**Accession Number:** 0002088432
**File Stem:** 0001213900-25-094944
**Filing Date:** 2025-10
**Character Count:** 20166
**Document Hash:** 80e9f65c3b07ffc05cda37576096f072
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-094944.hdr.sgml**: 20251002

**ACCESSION NUMBER**: 0001213900-25-094944

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251002

**DATE AS OF CHANGE**: 20251002

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Drugs Made In America Acquisition II Corp.
- **CENTRAL INDEX KEY:** 0002040475
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-95248
- **FILM NUMBER:** 251366972

**BUSINESS ADDRESS:**
- **STREET 1:** 1 EAST BROWARD BOULEVARD
- **STREET 2:** SUITE 700
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301
- **BUSINESS PHONE:** 954-870-3104

**MAIL ADDRESS:**
- **STREET 1:** 1 EAST BROWARD BOULEVARD
- **STREET 2:** SUITE 700
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Drugs Made In America Acquisition II LLC
- **CENTRAL INDEX KEY:** 0002088432

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 1 EAST BROWARD BOULEVARD, SUITE 700
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301
- **BUSINESS PHONE:** 954-870-3099

**MAIL ADDRESS:**
- **STREET 1:** 1 EAST BROWARD BOULEVARD, SUITE 700
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301

## Exhibit 99.1

**EXHIBIT 99.1**

**JOINT FILING AGREEMENT**

The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D with respect to the Ordinary Shares of Drugs Made In America Acquisition II Corp. beneficially owned by each of them. This Joint Filing Agreement shall be included as an exhibit to such Schedule 13D.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of the 1<sup>st</sup> day of October, 2025.

---

| | |
|:---|:---|
| DRUGS MADE IN AMERICA ACQUISITION II LLC | DRUGS MADE IN AMERICA ACQUISITION II LLC |
| By: | /s/ Lynn Stockwell |
| Name: | Lynn Stockwell |
| Title: | Authorized Person |
| LYNN STOCKWELL | LYNN STOCKWELL |
| Signature: | Signature: |
| /s/ Lynn Stockwell | /s/ Lynn Stockwell |
| (in personal capacity) | (in personal capacity) |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Drugs Made In America Acquisition II Corp.**

*(Name of Issuer)*

**Ordinary Shares**

*(Title of Class of Securities)*

**G2851K104**

*(CUSIP Number)*

**Lynn Stockwell**<br>c/o Drugs Made ln America Acq. II Corp.<br>1 East Broward Boulevard, Suite 700<br>Fort Lauderdale FL 33301<br>954 870-3099

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**10/01/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **G2851K104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Drugs Made In America Acquisition II LLC** | Name of reporting person<br>**Drugs Made In America Acquisition II LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**6708333.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**6708333.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**6708333.00** | Aggregate amount beneficially owned by each reporting person<br>**6708333.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**10.2%** | Percent of class represented by amount in Row (11)<br>**10.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** (1) Consists of 6,708,333 ordinary shares, including 700,000 ordinary shares underlying 700,000 units, with each unit consisting of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination. Excludes 70,000 ordinary shares which will be issued upon conversion of 700,000 rights upon consummation of the Issuer's initial business combination.

(2) Percentage is calculated based on 65,575,000 ordinary shares issued and outstanding, including 50,000,000 shares underlying 50,000,000 outstanding units, each unit consisting of one ordinary share and one right to receive one-tenth (1/10) of one ordinary share upon the consummation of an initial business combination.

| **CUSIP No.** | **G2851K104** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Lynn Stockwell** | Name of reporting person<br>**Lynn Stockwell** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**ISRAEL** | Citizenship or place of organization<br>**ISRAEL** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**6708333.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**6708333.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**6708333.00** | Aggregate amount beneficially owned by each reporting person<br>**6708333.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**10.2%** | Percent of class represented by amount in Row (11)<br>**10.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** (1) Consists of 6,708,333 ordinary shares, including 700,000 ordinary shares underlying 700,000 units, with each unit consisting of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination. Excludes 70,000 ordinary shares which will be issued upon conversion of 700,000 rights upon consummation of the Issuer's initial business combination.

(2) Percentage is calculated based on 65,575,000 ordinary shares issued and outstanding, including 50,000,000 shares underlying 50,000,000 outstanding units, each unit consisting of one ordinary share and one right to receive one-tenth (1/10) of one ordinary share upon the consummation of an initial business combination.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares

**(b) Name of Issuer:**
Drugs Made In America Acquisition II Corp.

**(c) Address of Issuer's Principal Executive Offices:**
2 PELICAN DR., Fort Lauderdale, FL, 33301

**Item 4. Purpose of Transaction**

The information set forth in Item 3 above is incorporated into this Item 4 by reference.  The Reporting Persons may acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions.

Lynn Stockwell serves as Chief Executive Officer and Executive Chair of the board of directors of the Issuer, and, in such capacity, may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

 Except as described in this Statement, each of the Reporting Person does not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein.  The Reporting Persons acquired the shares reported herein for investment purposes.  The Reporting Persons intend to review their investment in the Issuer on a continuing basis.  Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the ordinary shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, engaging in communications with management and the Board of Directors of the Issuer, engaging in discussions with shareholders of the Issuer or other third parties about the Issuer and the Reporting Persons' investment, including potential business combinations or dispositions involving the Issuer or certain of its businesses, making recommendations or proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including board composition), potential business combinations or dispositions involving the Issuer or certain of its businesses, or suggestions for improving the Issuer's financial and/or operational performance, purchasing additional ordinary shares and/or other securities, selling some or all of its ordinary shares and/or other securities, or changing its intention with respect to any and all matters referred to in Item 4.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information set forth in the cover pages of this Statement (including, but not limited to, footnotes to such information) are incorporated herein by reference.

**(b)**
The information set forth in the cover pages of this Statement (including, but not limited to, footnotes to such information) are incorporated herein by reference.

**(c)**
On September 11, 2024, the Issuer issued to the sponsor an aggregate of 44,722,222 ordinary shares for an aggregate purchase price of $35,000.  On February 2025, the Sponsor surrendered and forfeited 18,847,722 ordinary shares to the Issuer for no consideration, following which the sponsor held 25,875,000 ordinary shares. In May 2025, the Sponsor surrendered and forfeited an additional 11,500,000 ordinary shares to the Company for no consideration, following which the Sponsor holds 14,375,000 Founder Shares.

On September 26, 2025, simultaneously with the closing of the IPO, the sponsor acquired 700,000 private units at $10 per unit for an aggregate purchase price of $700,000.

As of September 26, 2025, the sponsor transferred an aggregate of 400,000 ordinary shares to certain of the Issuer's officers and directors for no consideration.

As of September 26, 2025, pursuant to share transfer agreements, the sponsor transferred an aggregate of 7,966,667 ordinary shares for consideration ranging from no consideration to $1.50 per share.

Except as set forth in this Statement, the Reporting Persons have not engaged in any transaction during the past 60 days with respect to the ordinary shares of the Issuer.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information set forth in Items 3, 4 and 5 of this Statement is hereby incorporated by reference into this Item 6, as applicable.

Securities Subscription Agreement between the Issuer and Sponsor

On September 11, 2024, the Company issued to the Sponsor an aggregate of 44,722,222 shares (the "Founder Shares") ordinary shares, par value $0.0001 per share, in exchange for $35,000 or approximately $0.0008 per share. In February 2025, the Sponsor surrendered and forfeited 18,847,722 ordinary shares to the Company for no consideration. In May 2025, the Sponsor surrendered and forfeited an additional 11,500,000 ordinary shares to the Company for no consideration, following which the Sponsor held 14,375,000 Founder Shares. The description of the Securities Subscription Agreement is qualified in its entirety by reference to the full text of such agreement, a copy of which was filed as Exhibit 10.8 to the Registration Statement on Form S-1 initially filed by the Issuer with the SEC on May 6, 2025 (and is incorporated by reference herein as Exhibit 10.1).

Letter Agreement

On September 24, 2025, in connection with the effectiveness of the registration statement filed in connection with the IPO, the Reporting Persons entered into a letter agreement (the "letter agreement") with the Issuer, pursuant to which the Reporting Persons agreed, subject to certain customary exceptions:

(i) to waive:  (1) their redemption rights with respect to any shares held by them, as applicable, in connection with the completion of the Issuer's initial business combination; (2) their redemption rights with respect to any shares held by them in connection with a shareholder vote to amend the Issuer's amended and restated memorandum and articles of association (A) to modify the substance or timing of the Issuer's obligation to allow redemption in connection with its initial business combination or to redeem 100% of its public shares if the Issuer does not complete its initial business combination within the completion window or (B) with respect to any other material provisions relating to shareholders' rights or pre-initial business combination activity; and (3) their rights to liquidating distributions from the trust account with respect to any founder shares and private shares they hold if the Company fails to complete its initial business combination within the completion window (although they will be entitled to liquidating distributions from the trust account with respect to any public shares they hold if the Issuer fails to complete its initial business combination within the completion window);

(ii) to vote any shares held by them in favor of the Issuer's initial business combination; and

(iii) not to transfer, assign or sell any of their founder shares or the private units, including the underlying private shares and private rights, until the earlier to occur of:  (i) with respect to 50% of the founder shares and private units, the earlier of six months after the date of the consummation of the Issuer's initial business combination and the date on which the closing price of the ordinary shares equals or exceeds $12.50 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the initial business combination and (ii) with respect to the remaining 50% of the founder shares and private units, six months after the date of the consummation of the Issuer's initial business combination, or earlier, in either case, if, subsequent to its initial business combination, the Issuer consummates a liquidation, merger, share exchange or other similar transaction which results in all of its shareholders having the right to exchange their ordinary shares for cash, securities or other property (except with respect to permitted transferees).

Registration Rights Agreement

On September 24, 2025, in connection with the IPO, the Issuer, the Sponsor and other security holders entered into a registration rights agreement with the Issuer, pursuant to which the Sponsor was granted certain demand and "piggyback" registration rights, which will be subject to customary conditions and limitations.

Private Units Subscription Agreement

On September 24, 2025, in connection with the effectiveness of the registration statement filed in connection with the IPO, the sponsor entered into a private units purchase agreement (the "purchase agreement") with the Issuer, pursuant to which the sponsor purchased an aggregate of 700,000 private units at a price of $10.00 per unit ($7,000,000 in the aggregate) in a private placement that closed simultaneously with the closing of the Issuer's IPO.

References to and descriptions of the Securities Subscription Agreement, Letter Agreement, Registration Rights Agreement and the Private Units Subscription Agreement herein are qualified in their entirety by reference to the Securities Subscription Agreement, Letter Agreement, Registration Rights Agreement and the Private Units Subscription Agreement, which are attached as exhibits hereto and incorporated herein by reference.

Except as described herein, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Persons named in Item 2 above or between any such Reporting Persons and any other person with respect to any securities of the Issuer.

Joint Filing Agreement

Pursuant to Rule 13d-1(k) promulgated under the Exchange Act, the Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed hereto as Exhibit 99.1, with respect to the joint filing of this Schedule 13D and any amendment or amendments thereto.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Drugs Made In America Acquisition II LLC

**Signature:** /s/ Lynn Stockwell

**Name/Title:** Lynn Stockwell, Managing Member

**Date:** 10/02/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Lynn Stockwell

**Signature:** /s/ Lynn Stockwell

**Name/Title:** Lynn Stockwell, Managing Member

**Date:** 10/02/2025